<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Rare Disease Treatment Unexpectedly Rejected by the FDA
Image Overlay - Rare Disease Treatment Unexpectedly Rejected by the FDA

Rare Disease Treatment Unexpectedly Rejected by the FDA

September 4, 2019

Rare Disease Treatment Unexpectedly Rejected by the FDA

In a surprise decision, the U.S. Food and Drug Administration has rejected Sarepta’s experimental exon-skipping drug Vyondys 53 (golodirsen) for the treatment of Duchenne muscular dystrophy, citing risks of both infection and kidney toxicity. Yourway is dedicated to supporting clinical trials for advanced therapies for orphan diseases.

 Back to Index
Media

Upcoming Events

Clinical Outsourcing Group (COG)

October 21-22, 2025
Burlingame, California

Precision in Pharma Supply Chain & Logistics Summit

November 17-18, 2025
Revere Hotel Boston Common

Media

Articles

Case study: Coordinating a complex intercontinental shipment on a short timeline

Open chat
Come chat with us!
Hello! How can I help you?